DVAX 10.10 ▲ 0.00% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Dynavax Technologies Corp...

    NASDAQ: DVAX · Real-Time Price · USD
    10.10
    0.00 (0.00%)
    At close: Oct 03, 2025, 3:59 PM
    10.04
    -0.59%
    After-hours: Oct 03, 2025, 05:55 PM EDT
    0.00%
    Bid 9.83
    Market Cap 1.18B
    Revenue (ttm) 316.27M
    Net Income (ttm) -52.73M
    EPS (ttm) -0.47
    PE Ratio (ttm) -21.49
    Forward PE 21.04
    Analyst Buy
    Dividends n/a
    Ask 10.34
    Volume 1,147,371
    Avg. Volume (20D) 1,844,858.1
    Open 10.12
    Previous Close 10.10
    Day's Range 10.02 - 10.18
    52-Week Range 9.20 - 14.63
    Beta 1.13
    Ex-Dividend Date n/a

    About DVAX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol DVAX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for DVAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Dynavax Technologies Corporation is scheduled to release its earnings on Nov 6, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    -1.05%
    Shares of vaccine companies are trading lower foll... Unlock content with Pro Subscription
    1 month ago
    +5.09%
    Dynavax Technologies shares are trading higher after the company announced its shingles vaccine candidate Z-1018 has shown efficacy in its Phase 1/2 trial.
    news image

    6 days ago · seekingalpha.com

    3 Of My Favorite Biotech Stocks Under $10

    Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited ...

    news image

    1 month ago · reuters.com

    Dynavax's shingles vaccine shows similar immune response to GSK's shot in study

    Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-s...

    news image

    1 month ago · seekingalpha.com

    Dynavax Technologies: A Dip To Accumulate

    Dynavax delivered strong Q2 results, beating expectations and narrowing guidance, and Heplisav-B continued to sport market share gains and profitability. Heplisav-B is best-in-class in its niche, and ...

    news image

    1 month ago · seekingalpha.com

    Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript

    Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Donn Casale - Senior VP & Chief Commercial Officer Kelly MacDonald - Sen...

    news image

    1 month ago · zacks.com

    Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

    Dynavax Technologies (DVAX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.08 per share a year ago.

    news image

    1 month ago · fool.com

    Dynavax (DVAX) Q2 Revenue Jumps 29%

    Dynavax (DVAX) Q2 Revenue Jumps 29%

    Add to Watchlist